Biogens IMRALDI an Adalimumab Biosimilar Candidate Referencing Humira Granted Positive Opinion by Committee for Medicinal Products for Human Use

If approved IMRALDI would be the third antiTNF biosimilar in Biogens portfolio in Europe helping to expand affordable therapy options and increase access for patients with chronic antiinflammatory disorders such as rheumatoid arthri...